News
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.
A research team from the University of Oklahoma has pioneered a method that could accelerate drug discovery and reduce ...
2d
BusinessWorld on MSNFDA expects speedier drug permit processTHE new Food and Drug Administration (FDA) application procedures are expected to reduce the drug permit process by as much ...
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...
The FDA has communicated to Stealth BioTherapeutics that it would not meet elamipretide’s PDUFA target date for the treatment of Barth syndrome.
The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...
Explore cutting-edge methods for detecting alcohol biomarkers and drugs of abuse using alternative sample matrices.
Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on ...
Novo Nordisk said the Food and Drug Administration has accepted its submission of a new drug application for a Wegovy pill to treat obesity. The Bagsvaerd, Denmark, company said Friday that if the ...
Investing.com -- Novo Nordisk (NYSE: NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results